Aloimune • Imunologia da Reprodução

71 3235-0958 • 99197-8344

Espaço Científico

Encontre conteúdos relacionados à área de Medicina Fetal, Imunologia da Reprodução e assuntos ligados a área de fertilidade em geral.
Home » Espaço Científico

11 de setembro de 2015

Heparina e FIV

Heparina e FIV

IVF failures: maternal thrombophilia as a possible cause
Autores: Dzhandzhgava e Bitsadze

Geoargian Med News. 2005 Jul-Aug; (124-125):23-6

It is studied the association between thrombophilia and failure to achieve pregnancy after IVF. The study group included 55 patients aged 24-45 years, with history of infertility I and II (unexplained genesis). 38 women were with a history of IVF failures and 17 — without such history. The comparison group consisted of 30 women pregnant after IVF (male factor). The control group was comprised of 50 patients with physiological course of pregnancy. In the study group thrombophilia was verified in 90% of cases; in the group of comparison — 30%; in control group — 26% (p<0,05). In the study group the multigenic defects were verified in 90% of cases. The polymorphism of PAI-1 was found in 69% women with a history of IVF failures and in 35% in group without the history of IVF failures. In the group of comparison polymorphism was found in 10% of women and in control group — 8% (p<0,05). In the study group differential antithrombotic prophylaxis was conducted with the result of 36,4% viable pregnancy (20 women of 55). The endpoint for success was a live birth. These data suggest that inherited thrombophilia may play a role in the etiology of IVF failures. The differential antithrombotic prophylaxis reduces the abortion rate but also lowers the risk for development retardation, premature birth and preeclampsia.

AV. Anita Garibaldi, nº 1555, Sala 105 - Centro Médico Garibaldi
CEP 40210-902, Salvador, Bahia
Telefax 71 3235-0958 / 99197-8344
Responsável Técnico - Dr. Manoel Sarno - CREMEB - 13410
© Todos os direitos reservados - 2015 - CREMEB: 13410